DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Transactions / P•••••••
warburg pincus led investor group agrees to acquire controlling interest in pantherx rare
Exit to a strategic buyerannouncedannounced Jul 13, 2026Fact
What happened
- Target
- P•••••••
- Platform
- not an add-on on record
- Control
- unknown
- Share acquired
- unknown
- Industry
- healthcare / health care, pharma
- Target location
- unknown
- Seller kind
- Sponsor
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
10 named
Buy side
- “N•• Y••• a•• P••••••••• – July 13 th – Warburg Pincus, the pioneer of global growth investing, today announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in P••••••• ® Rare, the leading independent rare pharmacy in the United States, from N••••• Partners, G”
Sell side
- “N••••• P•••••••• L•• is a middle-market private equity firm based in Providence, Rhode Island, that focuses on investments in three sectors: healthcare, industrials, and services.”
Advisory side
- J••• M••••• S••••••••• L••Financial adviserconfirmed“J••• M••••• S••••••••• L•• served as financial advisor to Warburg Pincus.”
- F••••••••• L••Legal adviserconfirmed“F••••••••• L•• served as legal counsel to ADIA.”
- C••••• G•••••••Legal adviserconfirmed“C••••• G••••••• served as legal counsel to Warburg Pincus.”
- R•••• • G••• L••Legal adviserconfirmed“R•••• & G••• served as legal counsel to P•••••••.”
- C••••••••• P••••••• L••Sell-side adviserconfirmed“C••••••••• Partners and G•••••• S•••• • C•• L•• served as financial advisors to P•••••••.”
- “C••••••••• Partners and G•••••• S•••• • C•• L•• served as financial advisors to P•••••••.”
Side not stated
- “We are grateful for the partnership and support from N••••• Partners, General Atlantic, and The Vistria Group, whose investment helped expand our impact for patients and shape the company we are today,” said B•••• N••••, Chief Executive Officer of P•••••••.”
- “N•• Y••• a•• P••••••••• – July 13 th – Warburg Pincus, the pioneer of global growth investing, today announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in P••••••• ® Rare, the leading independent rare pharmacy in the United States, from N••••• Partners, G”
Evidence
“N•• Y••• a•• P••••••••• – July 13 th – Warburg Pincus, the pioneer of global growth investing, today announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in P••••••• ® Rare, the leading independent rare pharmacy in the United States, from N••••• Partners, General Atlantic, and The Vistria Group.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 14, 2026